Department of Laboratory Medicine, Kangnam Sacred Heart Hospital, Hallym University College of Medicine, Seoul, South Korea.
Department of Laboratory Medicine, Dongtan Sacred Heart Hospital, Hallym University College of Medicine, Hwaseong, South Korea.
J Clin Microbiol. 2021 Nov 18;59(12):e0178821. doi: 10.1128/JCM.01788-21. Epub 2021 Oct 6.
Reliable results for serological positivity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody after the second dose of AstraZeneca (AZ) vaccination are important to estimate the real efficacy of vaccination. We evaluated positivity rates and changes in semiquantitative antibody titers before and after the first and second ChAdOx1 nCoV-19 vaccinations using five SARS-CoV-2 antibody assays, including two surrogate virus neutralization tests. A total of 674 serum samples were obtained from 228 participants during three blood sampling periods. A questionnaire on symptoms, severity, and adverse reaction duration was completed by participants after the second vaccination. The overall positive rates for all assays were 0.0 to 0.9% before vaccination, 66.2 to 92.5% after the first vaccination, and 98.2 to 100.0% after the second vaccination. Median antibody titers in five assays after the second dose of vaccination were increased compared to those after the first dose (106.4-fold increase for Roche total antibody, 3.6-fold for Abbott IgG, 3.6-fold for Siemens, 1.2-fold for SD Biosensor V1 neutralizing antibody, and 2.2-fold for GenScript neutralizing antibody). Adverse reactions were reduced after the second dose in 89.9% of participants compared to after the first dose. Overall, the second vaccination led to almost 100% positivity rates based on these SARS-CoV-2 antibody assays. The results should be interpreted with caution, considering the characteristics of the applied assays. Our findings could inform decisions regarding vaccination and the use of immunoassays, thus contributing to SARS-CoV-2 pandemic control.
在接种阿斯利康（AZ）疫苗第二剂后，血清学对严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）抗体呈阳性的可靠结果对于评估疫苗的真实疗效非常重要。我们使用五种 SARS-CoV-2 抗体检测方法（包括两种替代病毒中和试验）评估了 ChAdOx1 nCoV-19 疫苗接种前后第一剂和第二剂的阳性率和半定量抗体滴度变化。在三个采血期内，从 228 名参与者中获得了 674 份血清样本。参与者在第二次接种后完成了一份关于症状、严重程度和不良反应持续时间的问卷。所有检测方法在接种前的总体阳性率为 0.0 至 0.9%，接种第一剂后为 66.2 至 92.5%，接种第二剂后为 98.2 至 100.0%。与第一剂相比，五种检测方法在第二剂接种后的抗体滴度中位数均有所增加（罗氏总抗体增加 106.4 倍，雅培 IgG 增加 3.6 倍，西门子增加 3.6 倍，SD Biosensor V1 中和抗体增加 1.2 倍，GenScript 中和抗体增加 2.2 倍）。与第一剂相比，第二次接种后 89.9%的参与者不良反应减少。总体而言，基于这些 SARS-CoV-2 抗体检测方法，第二次接种后几乎达到 100%的阳性率。考虑到应用检测方法的特点，这些结果的解释应谨慎。我们的研究结果可为疫苗接种和免疫分析的使用决策提供信息，从而有助于控制 SARS-CoV-2 大流行。
